rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2024-55-64rsp-3513Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESВолчаночный нефрит – современные аспекты диагностики и терапии. Часть ILupus nephritis – modern aspects of diagnosis and therapy. Part Ihttps://orcid.org/0000-0002-5206-1732СоловьевС. К.SolovyevS. K.

Соловьев Сергей Константинович

115522, Москва, Каширское шоссе, 34а

Sergey K. Solovyev

115522, Moscow, Kashirskoye Highway, 34A

sksoloviev@mail.ruhttps://orcid.org/0000-0002-4275-0315КозловскаяН. Л.KozlovskayaN. L.

127473, Москва, ул. Делегатская, 20, стр. 1

Natalia L. Kozlovskaya

127473, Moscow, Delegatskaya str., 20, building 1

https://orcid.org/0000-0002-1663-7810АсееваЕ. А.AseevaE. A.

115522, Москва, Каширское шоссе, 34а

Elena A. Aseeva

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0001-7847-1679БарановА. А.BaranovA. A.

150000, Ярославль, ул. Революционная, 5

Andrey A. Baranov

150000, Yaroslavl, Revolyutsionnaya str., 5

https://orcid.org/0000-0002-4160-7218НикишинаН. Ю.NikishinaN. Yu.

115522, Москва, Каширское шоссе, 34а

Nina Yu. Nikishina

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.

115522, Москва, Каширское шоссе, 34а;

119991, Москва, ул. Трубецкая, 8, стр. 2

Evgeny L. Nasonov

115522, Moscow, Kashirskoye Highway, 34A;

119991, Moscow, Trubetskaya str., 8, building 2

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБОУ ВО «Московский государственный медико-стоматологический университет имени А.И. Евдокимова» Минздрава РоссииРоссияA.I. Yevdokimov Moscow State University of Medicine and DentistryRussian FederationФГБОУ ВО «Ярославский государственный медицинский университет» Минздрава РоссииРоссияYaroslavl State Medical UniversityRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияV.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)Russian Federation2024290220246215564Copyright © Соловьев С.К., Козловская Н.Л., Асеева Е.А., Баранов А.А., Никишина Н.Ю., Насонов Е.Л., 20242024Соловьев С.К., Козловская Н.Л., Асеева Е.А., Баранов А.А., Никишина Н.Ю., Насонов Е.Л.Solovyev S.K., Kozlovskaya N.L., Aseeva E.A., Baranov A.A., Nikishina N.Y., Nasonov E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3513

Волчаночный нефрит (ВН) по праву считается одним из наиболее частых среди тяжелых проявлений системной красной волчанки (СКВ); различные его клинические признаки встречаются не менее чем у 50% больных СКВ как в дебюте, так и на различных сроках болезни, а развитие ВН считается одним из наиболее важных предикторов смертности при СКВ. Среди различных его вариантов преобладает диффузный пролиферативный ВН с клинико-морфологическими признаками прогрессирования и быстрым развитием терминальной почечной недостаточности. Диагноз СКВ устанавливается на основании диагностических классификационных критериев Европейского альянса ревматологических ассоциаций/ Американской коллегии ревматологов (EULAR/ACR, European Alliance of Associations for Rheumatology/ American College of Rheumatology) 2019 г. Для подтверждения диагноза, оценки прогноза и выбора тактики лечения заболевания всем пациентам при отсутствии противопоказаний необходимо проведение биопсии почки. Помимо ВН, в спектр ассоциированных с СКВ вариантов поражения почек входят сосудистая патология, представленная тромботической микроангиопатией, волчаночной васкулопатией или васкулитом, тубулоинтерстициальное повреждение и волчаночная подоцитопатия.

Lupus nephritis (LN) is considered to be one of the most frequent severe manifestations of systemic lupus erythematosus (SLE), its various colonic manifestations occur in at least 50% of SLE patients, both at the onset and at various stages of the disease, and develop LN is considered one of the most important predictors of mortality in SLE. The structure of nephritis is dominated by diffuse proliferative LN with clinical and morphological signs of progression and the rapid development of terminal renal failure. SLE is diagnosed based on the 2019 EULAR/ACR (European Alliance of Associations for Rheumatology/American College of Rheumatology) diagnostic classification criteria. To confirm the diagnosis, evaluate the prognosis, and choose the tactics of treating the dis-ease, all patients in the absence of contraindications require a kidney biopsy. In addition to LN, the spectrum of SLE-associated renal lesions includes vascular pathology represented by thrombotic microangiopathy, lupus vasculopathy or vasculitis, tubulointerstitial injury, and lupus podocytopathy.

системная красная волчанкаволчаночный нефритsystemic lupus erythematosuslupus nephritisИсследование проводилось в рамках научной темы FURS-2022-003.ReferencesНасонов ЕЛ, Соловьев СК, Аршинов АВ. Системная красная волчанка: история и современность. Научно-практическая ревматология. 2022;60(4):397-412. doi: 10.47360/1995-4484-2022-397-412Nasonov EL, Soloviev SK, Arshinov AV. Systemic lupus erythematosus: History and modernity. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(4):397-412 (In Russ.) doi: 10.47360/1995-4484-2022-397-412Соловьев СК, Асеева ЕА, Попкова ТВ, Лила АМ, Мазуров ВИ, Насонов ЕЛ. Системная красная волчанка: новые горизонты диагностики и терапии. Научно-практическая ревматология. 2020;58(1):5-14. doi: 10.14412/1995-4484-2020-5-14Solovyev SK, Aseeva EA, Popkova TV, Lila AM, Mazurov VI, Nasonov EL. Systemic lupus erythematosus: New horizons for diagnosis and therapy. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(1):5-14 (In Russ.) doi: 10.14412/1995-4484-2020-5-14Асеева ЕА, Лила АМ, Соловьев СК, Глухова СИ. Волчаночный нефрит как особый клинико-иммунологический фенотип системной красной волчанки. Современная ревматология. 2022;16(6):12-19. doi: 10.14412/1996-7012-2022-6-12-19Aseeva EA, Lila AM, Soloviev SK, Glukhova SI. Lupus nephritis as a specific clinical and immunological phenotype of systemic lupus erythematosus. Modern Rheumatology Journal. 2022; 16(6):12-19 (In Russ.) doi: 10.14412/1996-7012-2022-6-12-19Hanly JG, O’Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, et al. The frequency and outcome of lupus nephritis: Results from an international inception cohort study. Rheumatology (Oxford). 2016;55(2):252-262. doi: 10.1093/rheumatology/kev311Hanly JG, O’Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, et al. The frequency and outcome of lupus nephritis: Results from an international inception cohort study. Rheumatology (Oxford). 2016;55(2):252-262. doi: 10.1093/rheumatology/kev311Tektonidou MG, Dasgupta A, Ward MM. Risk of end-stage renal disease in patients with lupus nephritis, 1971–2015: A systematic review and bayesian meta-analysis. Arthritis Rheumatol. 2016;68(6):1432-1441. doi: 10.1002/art.39594Tektonidou MG, Dasgupta A, Ward MM. Risk of end-stage renal disease in patients with lupus nephritis, 1971–2015: A systematic review and bayesian meta-analysis. Arthritis Rheumatol. 2016;68(6):1432-1441. doi: 10.1002/art.39594Faurschou M, Dreyer L, Kamper AL, Starklint H, Jacobsen S. Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. Arthritis Care Res (Hoboken). 2010;62(6):873-880. doi: 10.1002/acr.20116Faurschou M, Dreyer L, Kamper AL, Starklint H, Jacobsen S. Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. Arthritis Care Res (Hoboken). 2010;62(6):873-880. doi: 10.1002/acr.20116Ward MM. Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996–2004. J Rheumatol. 2009;36(1):63-67. doi: 10.3899/jrheum.080625Ward MM. Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996–2004. J Rheumatol. 2009;36(1):63-67. doi: 10.3899/jrheum.080625Mahajan A, Amelio J, Gairy K, Kaur G, Levy RA, Roth D, et al. Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: A pragmatic review mapping disease severity and progression. Lupus. 2020;29(9):1011-1020. doi: 10.1177/0961203320932219Mahajan A, Amelio J, Gairy K, Kaur G, Levy RA, Roth D, et al. Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: A pragmatic review mapping disease severity and progression. Lupus. 2020;29(9):1011-1020. doi: 10.1177/0961203320932219Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 2013;65(8):2154-2160. doi: 10.1002/art.38006Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 2013;65(8):2154-2160. doi: 10.1002/art.38006Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54(8):2550-2557. doi: 10.1002/art.21955Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54(8):2550-2557. doi: 10.1002/art.21955Maningding E, Dall’Era M, Trupin L, Murphy LB, Yazdany J. Racial and ethnic differences in the prevalence and time to onset of manifestations of systemic lupus erythematosus: The California lupus surveillance project. Arthritis Care Res (Hoboken). 2020;72(5):622-629. doi: 10.1002/acr.23887Maningding E, Dall’Era M, Trupin L, Murphy LB, Yazdany J. Racial and ethnic differences in the prevalence and time to onset of manifestations of systemic lupus erythematosus: The California lupus surveillance project. Arthritis Care Res (Hoboken). 2020;72(5):622-629. doi: 10.1002/acr.23887Jakes RW, Bae SC, Louthrenoo W, Mok CC, Navarra SV, Kwon N. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: Prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken). 2012;64(2):159-168. doi: 10.1002/acr.20683Jakes RW, Bae SC, Louthrenoo W, Mok CC, Navarra SV, Kwon N. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: Prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken). 2012;64(2):159-168. doi: 10.1002/acr.20683Hoover PJ, Costenbader KH. Insights into the epidemiology and management of lupus nephritis from the US rheumatologist’s perspective. Kidney Int. 2016;90(3):487-492. doi: 10.1016/j.kint.2016.03.042Hoover PJ, Costenbader KH. Insights into the epidemiology and management of lupus nephritis from the US rheumatologist’s perspective. Kidney Int. 2016;90(3):487-492. doi: 10.1016/j.kint.2016.03.042Burgos PI, McGwin G Jr, Pons-Estel GJ, Reveille JD, Alarcón GS, Vilá LM. US patients of Hispanic and African ancestry develop lupus nephritis early in the disease course: Data from LUMINA, a multiethnic US cohort (LUMINA LXXIV). Ann Rheum Dis. 2011;70(2):393-394. doi: 10.1136/ard.2010.131482Burgos PI, McGwin G Jr, Pons-Estel GJ, Reveille JD, Alarcón GS, Vilá LM. US patients of Hispanic and African ancestry develop lupus nephritis early in the disease course: Data from LUMINA, a multiethnic US cohort (LUMINA LXXIV). Ann Rheum Dis. 2011;70(2):393-394. doi: 10.1136/ard.2010.131482Feldman CH, Hiraki LT, Liu J, Fischer MA, Solomon DH, Alarcón GS, et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000–2004. Arthritis Rheum. 2013;65(3):753-763. doi: 10.1002/art.37795Feldman CH, Hiraki LT, Liu J, Fischer MA, Solomon DH, Alarcón GS, et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000–2004. Arthritis Rheum. 2013;65(3):753-763. doi: 10.1002/art.37795Lanata CM, Nititham J, Taylor KE, Chung SA, Torgerson DG, Seldin MF, et al. Genetic contributions to lupus nephritis in a multiethnic cohort of systemic lupus erythematous patients. PLoS One. 2018;13(6):e0199003. doi: 10.1371/journal.pone.0199003Lanata CM, Nititham J, Taylor KE, Chung SA, Torgerson DG, Seldin MF, et al. Genetic contributions to lupus nephritis in a multiethnic cohort of systemic lupus erythematous patients. PLoS One. 2018;13(6):e0199003. doi: 10.1371/journal.pone.0199003Nee R, Martinez-Osorio J, Yuan CM, Little DJ, Watson MA, Agodoa L, et al. Survival disparity of African American versus non-African American patients with ESRD due to SLE. Am J Kidney Dis. 2015;66(4):630-637. doi: 10.1053/j.ajkd.2015.04.011Nee R, Martinez-Osorio J, Yuan CM, Little DJ, Watson MA, Agodoa L, et al. Survival disparity of African American versus nonAfrican American patients with ESRD due to SLE. Am J Kidney Dis. 2015;66(4):630-637. doi: 10.1053/j.ajkd.2015.04.011Korbet SM, Schwartz MM, Evans J, Lewis EJ; Collaborative Study Group. Severe lupus nephritis: Racial differences in presentation and outcome. J Am Soc Nephrol. 2007;18(1):244-254. doi: 10.1681/ASN.2006090992Korbet SM, Schwartz MM, Evans J, Lewis EJ; Collaborative Study Group. Severe lupus nephritis: Racial differences in presentation and outcome. J Am Soc Nephrol. 2007;18(1):244-254. doi: 10.1681/ASN.2006090992McCarty GA, Harley JB, Reichlin M. A distinctive autoantibody profile in black female patients with lupus nephritis. Arthritis Rheum. 1993;36(11):1560-1565. doi: 10.1002/art.1780361110McCarty GA, Harley JB, Reichlin M. A distinctive autoantibody profile in black female patients with lupus nephritis. Arthritis Rheum. 1993;36(11):1560-1565. doi: 10.1002/art.1780361110Hiraki LT, Feldman CH, Liu J, Alarcón GS, Fischer MA, Winkelmayer WC, et al. Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population. Arthritis Rheum. 2012;64(8):2669-2676. doi: 10.1002/art.34472Hiraki LT, Feldman CH, Liu J, Alarcón GS, Fischer MA, Winkelmayer WC, et al. Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population. Arthritis Rheum. 2012;64(8):2669-2676. doi: 10.1002/art.34472Tucker LB, Uribe AG, Fernández M, Vilá LM, McGwin G, Apte M, et al. Adolescent onset of lupus results in more aggressive disease and worse outcomes: Results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus. 2008;17(4):314-322. doi: 10.1177/0961203307087875Tucker LB, Uribe AG, Fernández M, Vilá LM, McGwin G, Apte M, et al. Adolescent onset of lupus results in more aggressive disease and worse outcomes: Results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus. 2008;17(4):314-322. doi: 10.1177/0961203307087875Yazdany J, Feldman CH, Liu J, Ward MM, Fischer MA, Costenbader KH. Quality of care for incident lupus nephritis among Medicaid beneficiaries in the United States. Arthritis Care Res (Hoboken). 2014;66(4):617-624. doi: 10.1002/acr.22182Yazdany J, Feldman CH, Liu J, Ward MM, Fischer MA, Costenbader KH. Quality of care for incident lupus nephritis among Medicaid beneficiaries in the United States. Arthritis Care Res (Hoboken). 2014;66(4):617-624. doi: 10.1002/acr.22182American College of Rheumatology Committee on Rheumatology Training and Workforce Issues; FitzGerald JD, Battistone M, Brown CR Jr, Cannella AC, Chakravarty E, et al. Regional distribution of adult rheumatologists. Arthritis Rheum. 2013;65(12):3017-3025. doi: 10.1002/art.38167American College of Rheumatology Committee on Rheumatology Training and Workforce Issues; FitzGerald JD, Battistone M, Brown CR Jr, Cannella AC, Chakravarty E, et al. Regional distribution of adult rheumatologists. Arthritis Rheum. 2013;65(12):3017-3025. doi: 10.1002/art.38167Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. doi: 10.1136/annrheumdis-2019-215089Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. doi: 10.1136/annrheumdis-2019-215089KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100:1-276. doi: 10.1016/j.kint.2021.05.021KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100:1-276. doi: 10.1016/j.kint.2021.05.021Ассоциация нефрологов, Научное общество нефрологов России, Общероссийская общественная организация нефрологов «Российское диализное общество». Клинические рекомендации. Диагностика и лечение волчаночного нефрита. М.;2021. URL: https://rusnephrology.org/wpcontent/uploads/2021/02/lupus.pdfAssociation of Nephrologists, Scientific Society of Nephrologists of Russia, All-Russian Public Organization of Nephrologists “Russian Dialysis Society” Clinical guidelines. Diagnosis and treatment of lupus nephritis. Moscow;2021 (In Russ.)]. URL: https://rusnephrology.org/wpcontent/uploads/2021/02/lupus.pdf [Accessed: DD Month YEAR].Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: Сlarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018; 93(4):789-796. doi: 10.1016/j.kint.2017.11.023Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: Сlarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018; 93(4):789-796. doi: 10.1016/j.kint.2017.11.023Насонова ВА. Системная красная волчанка. М.:Медицина;1972.Nasonova VA. Systemic lupus erythematosus. Moscow:Meditsina; 1972 (In Russ.)Тареева ИЕ. Волчаночный нефрит. М.:Медицина;1976.Tareeva IE. Lupus nephritis. Moscow:Meditsina;1976 (In Russ.)Parodis I, Tamirou F, Houssiau FA. Prediction of prognosis and renal outcome in lupus nephritis. Lupus Sci Med. 2020;7(1): 000389. doi: 10.1136/lupus-2020-000389Parodis I, Tamirou F, Houssiau FA. Prediction of prognosis and renal outcome in lupus nephritis. Lupus Sci Med. 2020;7(1): 000389. doi: 10.1136/lupus-2020-000389Wang H, Ren YL, Chang J, Gu L, Sun LY. A systematic review and meta-analysis of prevalence of biopsy-proven lupus nephritis. Arch Rheumatol. 2017;33(1):17-25. doi: 10.5606/ArchRheumatol.2017.6127Wang H, Ren YL, Chang J, Gu L, Sun LY. A systematic review and meta-analysis of prevalence of biopsy-proven lupus nephritis. Arch Rheumatol. 2017;33(1):17-25. doi: 10.5606/ArchRheumatol.2017.6127Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al.; European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11): 1771-1782. doi: 10.1136/annrheumdis-2012-201940Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al.; European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11): 1771-1782. doi: 10.1136/annrheumdis-2012-201940Bihl GR, Petri M, Fine DM. Kidney biopsy in lupus nephritis: Look before you leap. Nephrol Dial Transplant. 2006;21:1749-1752. doi: 10.1093/ndt/gfl159Bihl GR, Petri M, Fine DM. Kidney biopsy in lupus nephritis: Look before you leap. Nephrol Dial Transplant. 2006;21:1749-1752. doi: 10.1093/ndt/gfl159Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9): 1151-1159. doi: 10.1136/annrheumdis-2018-214819Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9): 1151-1159. doi: 10.1136/annrheumdis-2018-214819Giannico G, Fogo AB. Lupus nephritis: Is the kidney biopsy currently necessary in the management of lupus nephritis? Clin J Am Soc Nephrol. 2013;8(1):138-145. doi: 10.2215/CJN.03400412Giannico G, Fogo AB. Lupus nephritis: Is the kidney biopsy currently necessary in the management of lupus nephritis? Clin J Am Soc Nephrol. 2013;8(1):138-145. doi: 10.2215/CJN.03400412Fogo AB. Approach to renal biopsy. Am J Kidney Dis. 2003;42(4): 826-836.Fogo AB. Approach to renal biopsy. Am J Kidney Dis. 2003;42(4): 826-836.Anders HJ. Re-biopsy in lupus nephritis. Ann Transl Med. 2018;6(Suppl 1):41. doi: 10.21037/atm.2018.09.47Anders HJ. Re-biopsy in lupus nephritis. Ann Transl Med. 2018;6(Suppl 1):41. doi: 10.21037/atm.2018.09.47De Rosa M, Azzato F, Toblli JE, De Rosa G, Fuentes F, Nagaraja HN, et al. A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int. 2018;94(4):788-794. doi: 10.1016/j.kint.2018.05.021De Rosa M, Azzato F, Toblli JE, De Rosa G, Fuentes F, Nagaraja HN, et al. A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int. 2018;94(4):788-794. doi: 10.1016/j.kint.2018.05.021Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al.; International Society of Nephrology Working Group on the Classification of Lupus Nephritis; Renal Pathology Society Working Group on the Classification of Lupus Nephritis. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65(2):521-530. doi: 10.1111/j.1523-1755.2004.00443.xWeening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al.; International Society of Nephrology Working Group on the Classification of Lupus Nephritis; Renal Pathology Society Working Group on the Classification of Lupus Nephritis. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65(2):521-530. doi: 10.1111/j.1523-1755.2004.00443.xAlmaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol. 2017;12(5):825-835. doi: 10.2215/CJN.05780616Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol. 2017;12(5):825-835. doi: 10.2215/CJN.05780616Schwartz MM, Korbet SM, Lewis EJ. The prognosis and pathogenesis of severe lupus glomerulonephritis. Nephrol Dial Transplant. 2008;23:1298-1306. doi: 10.1093/ndt/gfm775Schwartz MM, Korbet SM, Lewis EJ. The prognosis and pathogenesis of severe lupus glomerulonephritis. Nephrol Dial Transplant. 2008;23:1298-1306. doi: 10.1093/ndt/gfm775Haring CM, Rietveld A, van den Brand JA, Berden JHM. Segmental and global subclasses of class IV lupus nephritis have similar renal outcomes. J Am Soc Nephrol. 2012;23:149-154. doi: 10.1681/ASN.2011060558Haring CM, Rietveld A, van den Brand JA, Berden JHM. Segmental and global subclasses of class IV lupus nephritis have similar renal outcomes. J Am Soc Nephrol. 2012;23:149-154. doi: 10.1681/ASN.2011060558Rovin BH, Caster DJ, Cattran DC, Gibson KL, Hogan JJ, Moeller MJ, et al.; Conference Participants. Management and treatment of glomerular diseases (part 2): Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int. 2019;95(2):281-295. doi: 10.1016/j.kint.2018.11.008Rovin BH, Caster DJ, Cattran DC, Gibson KL, Hogan JJ, Moeller MJ, et al.; Conference Participants. Management and treatment of glomerular diseases (part 2): Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int. 2019;95(2):281-295. doi: 10.1016/j.kint.2018.11.008Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: Clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018;93(4):789-796. doi: 10.1016/j.kint.2017.11.023Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: Clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018;93(4):789-796. doi: 10.1016/j.kint.2017.11.023Duqun C, Hu W. Lupus podocytopathy: A distinct entity of lupus nephritis. J Nephrol. 2018;31(5):629-634. doi: 10.1007/s40620-017-0463-13Duqun C, Hu W. Lupus podocytopathy: A distinct entity of lupus nephritis. J Nephrol. 2018;31(5):629-634. doi: 10.1007/s40620-017-0463-13Makino H, Haramoto T, Shikata K, Ogura T, Ota Z. Minimalchange nephrotic syndrome associated with systemic lupus erythematosus. Am J Nephrol. 1995;15(5):439-441. doi: 10.1159/000168880Makino H, Haramoto T, Shikata K, Ogura T, Ota Z. Minimalchange nephrotic syndrome associated with systemic lupus erythematosus. Am J Nephrol. 1995;15(5):439-441. doi: 10.1159/000168880Dube GK, Markowitz GS, Radhakrishnan J, Appel GB, D’Agati VD. Minimal change disease in systemic lupus erythematosus. Clin Nephrol. 2002;57(2):120-126. doi: 10.5414/cnp57120Dube GK, Markowitz GS, Radhakrishnan J, Appel GB, D’Agati VD. Minimal change disease in systemic lupus erythematosus. Clin Nephrol. 2002;57(2):120-126. doi: 10.5414/cnp57120Kraft SW, Schwartz MM, Korbet SM, Lewis EJ. Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol. 2005;16(1):175-179. doi: 10.1681/ASN.2004050350Kraft SW, Schwartz MM, Korbet SM, Lewis EJ. Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol. 2005;16(1):175-179. doi: 10.1681/ASN.2004050350Hertig A, Droz D, Lesavre P, Grünfeld JP, Rieu P. SLE and idiopathic nephrotic syndrome: Coincidence or not? Am J Kidney Dis. 2002;40(6):1179-1184. doi: 10.1053/ajkd.2002.36875Hertig A, Droz D, Lesavre P, Grünfeld JP, Rieu P. SLE and idiopathic nephrotic syndrome: Coincidence or not? Am J Kidney Dis. 2002;40(6):1179-1184. doi: 10.1053/ajkd.2002.36875Wang YT, Chou HH, Chen FF, Chen MJ, Chiou YY. A case of minimal-change nephrotic syndrome in pediatric lupus erythematosus: Just a coincidence? Lupus. 2006;15(4):244-247. doi: 10.1191/0961203306lu2285crWang YT, Chou HH, Chen FF, Chen MJ, Chiou YY. A case of minimal-change nephrotic syndrome in pediatric lupus erythematosus: Just a coincidence? Lupus. 2006;15(4):244-247. doi: 10.1191/0961203306lu2285crBomback AS, Markowitz GS. Lupus podocytopathy: A distinct entity. Clini J Am Soc Nephrol: CJASN. 2016;11(4):547-548. doi: 10.2215/CJN.01880216Bomback AS, Markowitz GS. Lupus podocytopathy: A distinct entity. Clini J Am Soc Nephrol: CJASN. 2016;11(4):547-548. doi: 10.2215/CJN.01880216Hu W, Chen Y, Wang S, Chen H, Liu Z, Zeng C, et al. Clinicalmorphological features and outcomes of lupus podocytopathy. Clin J Am Soc Nephrol. 2016;11(4):585-592. doi: 10.2215/CJN.06720615Hu W, Chen Y, Wang S, Chen H, Liu Z, Zeng C, et al. Clinicalmorphological features and outcomes of lupus podocytopathy. Clin J Am Soc Nephrol. 2016;11(4):585-592. doi: 10.2215/CJN.06720615Oliva-Damaso N, Payan J, Oliva-Damaso E, Pereda T, Bomback AS. Lupus podocytopathy: An overview. Adv Chronic Kidney Dis. 2019;26(5):369-375. doi: 10.1053/j.ackd.2019.08.011Oliva-Damaso N, Payan J, Oliva-Damaso E, Pereda T, Bomback AS. Lupus podocytopathy: An overview. Adv Chronic Kidney Dis. 2019;26(5):369-375. doi: 10.1053/j.ackd.2019.08.011Стариков ДВ, Козловская НЛ, Столяревич ЕС, Бондаренко ТВ, Волкова ОА. Особенности течения и трудности диагностики волчаночной подоцитопатии. Нефрология и диализ. 2022;24(4): 898-906. doi: 10.28996/2618-9801-2022-4-898-906Starikov DV, Kozlovskaya NL, Stolyarevich ES, Bondarenko TV, Volkova OA. Features of the course and diagnosis of lupus podocytopathy. Nephrology and Dialysis. 2022;24(4):898-906 (In Russ.) doi: 10.28996/2618-9801-2022-4-898-906George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371:654-666. doi: 10.1056/NEJMra1312353George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371:654-666. doi: 10.1056/NEJMra1312353Brocklebank V, Wood KM, Kavanagh D. Thrombotic microangiopathy and the kidney. Clin J Am Soc Nephrol. 2018;13:300-317. doi: 10.2215/CJN.00620117Brocklebank V, Wood KM, Kavanagh D. Thrombotic microangiopathy and the kidney. Clin J Am Soc Nephrol. 2018;13:300-317. doi: 10.2215/CJN.00620117Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer Hovinga J, et al.; International Working Group for Thrombotic Thrombocytopenic Purpura. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017;15(2):312-322. doi: 10.1111/jth.13571Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer Hovinga J, et al.; International Working Group for Thrombotic Thrombocytopenic Purpura. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017;15(2):312-322. doi: 10.1111/jth.13571Kotzen ES, Roy S, Jain K. Antiphospholipid syndrome nephropathy and other thrombotic microangiopathies among patients with systemic lupus erythematosus. Adv Chronic Kidney Dis. 2019;26(5):376-386. doi: 10.1053 /j.ackd. 2019.08.012Kotzen ES, Roy S, Jain K. Antiphospholipid syndrome nephropathy and other thrombotic microangiopathies among patients with systemic lupus erythematosus. Adv Chronic Kidney Dis. 2019;26(5):376-386. doi: 10.1053 /j.ackd. 2019.08.012Ding Y, Tan Y, Qu Z, Yu F. Renal microvascular lesions in lupus nephritis. Renal Failure. 2020;42(1):19-29. doi: 10.1080/0886022X.2019.1702057Ding Y, Tan Y, Qu Z, Yu F. Renal microvascular lesions in lupus nephritis. Renal Failure. 2020;42(1):19-29. doi: 10.1080/0886022X.2019.1702057Barrera-Vargas A, Rosado-Canto R, Merayo-Chalico J, ArreolaGuerra JM, Mejía-Vilet JM, Correa-Rotter R, et al. Renal thrombotic microangiopathy in proliferative lupus nephritis: Risk factors and clinical outcomes: A case-control study. J Clin Rheumatol. 2016;22(5):235-240. doi: 10.1097/RHU.0000000000000425Barrera-Vargas A, Rosado-Canto R, Merayo-Chalico J, ArreolaGuerra JM, Mejía-Vilet JM, Correa-Rotter R, et al. Renal thrombotic microangiopathy in proliferative lupus nephritis: Risk factors and clinical outcomes: A case-control study. J Clin Rheumatol. 2016;22(5):235-240. doi: 10.1097/RHU.0000000000000425Song D, Wu LH, Wang FM, Yang XW, Zhu D, Chen M, et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther. 2013;15(1):R12. doi: 10.1186/ar4142Song D, Wu LH, Wang FM, Yang XW, Zhu D, Chen M, et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther. 2013;15(1):R12. doi: 10.1186/ar4142Bajema IG, Chuia JS, Bruijn JA. TMA: Tell me about it. J Rheumatol. 2019;46(11):1425-1427. doi: 10.3899/jrheum.190447Bajema IG, Chuia JS, Bruijn JA. TMA: Tell me about it. J Rheumatol. 2019;46(11):1425-1427. doi: 10.3899/jrheum.190447Anders HJ, Weening JJ. Kidney disease in lupus is not always “Lupus nephritis”. Arthritis Res Ther. 2013;15(2):108. doi: 10.1186/ar4166Anders HJ, Weening JJ. Kidney disease in lupus is not always “Lupus nephritis”. Arthritis Res Ther. 2013;15(2):108. doi: 10.1186/ar4166Bridoux F, Vrtovsnik F, Noël C, Saunier P, Mougenot B, Lemaitre V, et al. Renal thrombotic microangiopathy in systemic lupus erythematosus: clinical correlations and long-term renal survival. Nephrol Dial Transplant. 1998;13(2):298-304. doi: 10.1093/oxfordjournals.ndt.a027822Bridoux F, Vrtovsnik F, Noël C, Saunier P, Mougenot B, Lemaitre V, et al. Renal thrombotic microangiopathy in systemic lupus erythematosus: clinical correlations and long-term renal survival. Nephrol Dial Transplant. 1998;13(2):298-304. doi: 10.1093/oxfordjournals.ndt.a027822Chua JS, Baelde HJ, Zandbergen M, Wilhelmus S, van Es LA, de Fijter JW, et al. Complement factor C4d is a common denominator in thrombotic microangiopathy. J Am Soc Nephrol. 2015;26(9):2239-2247. doi: 10.1681/ASN.2014050429Chua JS, Baelde HJ, Zandbergen M, Wilhelmus S, van Es LA, de Fijter JW, et al. Complement factor C4d is a common denominator in thrombotic microangiopathy. J Am Soc Nephrol. 2015;26(9):2239-2247. doi: 10.1681/ASN.2014050429Li C, Yap DYH, Chan G, Wen YB, Li H, Tang C, et al. Clinical outcomes and clinico-pathological correlations in lupus nephritis with kidney biopsy showing thrombotic microangiopathy. J Rheumatol. 2019;46(11):1478-1484. doi: 10.3899/jrheum.180773Li C, Yap DYH, Chan G, Wen YB, Li H, Tang C, et al. Clinical outcomes and clinico-pathological correlations in lupus nephritis with kidney biopsy showing thrombotic microangiopathy. J Rheumatol. 2019;46(11):1478-1484. doi: 10.3899/jrheum.180773Bienaime F, Legendre C, Terzi F, Canaud G. Antiphospholipid syndrome and kidney disease. Kidney Int. 2017;91:34-44. doi: 10.1016/j.kint.2016.06.026Bienaime F, Legendre C, Terzi F, Canaud G. Antiphospholipid syndrome and kidney disease. Kidney Int. 2017;91:34-44. doi: 10.1016/j.kint.2016.06.026Tektonidou MG. Antiphospholipid syndrome nephropathy: From pathogenesis to treatment. Front Immunol. 2018;9:1181. doi: 10.3389/fimmu.2018.01181Tektonidou MG. Antiphospholipid syndrome nephropathy: From pathogenesis to treatment. Front Immunol. 2018;9:1181. doi: 10.3389/fimmu.2018.01181Starck M, Abedinpour F, Dendorfer U, Wagner-Czekalla J, Pachmann M, Mann JF, et al. Acquired thrombotic thrombocytopenic purpura as the presenting symptom of systemic lupus erythematosus. Successful treatment with plasma exchange and immunosuppression – Report of two cases. Eur J Haematol. 2005;75(5):436-440. doi: 10.1111/j.1600-0609.2005.00526.xStarck M, Abedinpour F, Dendorfer U, Wagner-Czekalla J, Pachmann M, Mann JF, et al. Acquired thrombotic thrombocytopenic purpura as the presenting symptom of systemic lupus erythematosus. Successful treatment with plasma exchange and immunosuppression – Report of two cases. Eur J Haematol. 2005;75(5):436-440. doi: 10.1111/j.1600-0609.2005.00526.xGeorge JN, Vesely SK, James JA. Overlapping features of thrombotic thrombocytopenic purpura and systemic lupus erythematosus. South Med J. 2007;100(5)512-514. doi: 10.1097/SMJ.0b013e318046583fGeorge JN, Vesely SK, James JA. Overlapping features of thrombotic thrombocytopenic purpura and systemic lupus erythematosus. South Med J. 2007;100(5)512-514. doi: 10.1097/SMJ.0b013e318046583fMejia-Vilet JM, Gómez-Ruiz IA, Cruz C, Méndez-Pérez RA, Comunidad-Bonilla RA, Uribe-Uribe NO, et al. Alternative complement pathway activation in thrombotic microangiopathy associated with lupus nephritis. Clin Rheumatol. 2021;40(6):2233-2242. doi: 10.1007/s10067-020-05499-1Mejia-Vilet JM, Gómez-Ruiz IA, Cruz C, Méndez-Pérez RA, Comunidad-Bonilla RA, Uribe-Uribe NO, et al. Alternative complement pathway activation in thrombotic microangiopathy associated with lupus nephritis. Clin Rheumatol. 2021;40(6):2233-2242. doi: 10.1007/s10067-020-05499-1Насонов ЕЛ, Решетняк ТМ, Алекберова ЗС. Тромботическая микроангиопатия в ревматологии: связь тромбовоспаления и аутоиммунитета. Терапевтический архив. 2020;92(5):4-14. doi: 10.26442/00403660.2020.05.000697Nasonov EL, Reshetnyak TM, Alekberova ZS. Thrombotic microangiopathy in rheumatology: A link between thrombosis and autoimmunity. Terapevticheskii arkhiv. 2020;92(5):4-14 (In Russ.) doi: 10.26442/00403660.2020.05.000697Kello N, El Khoury L, Marder G. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature. Semin Arthritis Rheum. 2019;49:74-83. doi: 10.1016/j.semarthrit.2018.11.005Kello N, El Khoury L, Marder G. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature. Semin Arthritis Rheum. 2019;49:74-83. doi: 10.1016/j.semarthrit.2018.11.005Park MH, Caselman N, Ulmer S, Weitz IC. Complement-mediated thrombotic microangiopa-thy associated with lupus nephritis. Blood Adv. 2018;2(16):2090-2094. doi: 10.1182/bloodadvances.2018019596Park MH, Caselman N, Ulmer S, Weitz IC. Complement-mediated thrombotic microangiopa-thy associated with lupus nephritis. Blood Adv. 2018;2(16):2090-2094. doi: 10.1182/bloodadvances.2018019596Kronbichler A, Frank R, Kirschfink M, Szilágyi Á, Csuka D, Prohászka Z, et al. Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: A case report. Medicine (Baltimore). 2014;93(26):e143. doi: 10.1097/MD.0000000000000143Kronbichler A, Frank R, Kirschfink M, Szilágyi Á, Csuka D, Prohászka Z, et al. Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: A case report. Medicine (Baltimore). 2014;93(26):e143. doi: 10.1097/MD.0000000000000143López-Benjume B, Rodríguez-Pintó I, Amigo MC, Erkan D, Shoenfeld Y, Cervera R, et al.; on behalf the CAPS Registry Project Group/European Forum on Antiphospholipid Antibodies. Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis from the “CAPS Registry”. Autoimmun Rev. 2022;21(4):103055. doi: 10.1016/j.autrev.2022.103055López-Benjume B, Rodríguez-Pintó I, Amigo MC, Erkan D, Shoenfeld Y, Cervera R, et al.; on behalf the CAPS Registry Project Group/European Forum on Antiphospholipid Antibodies. Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis from the “CAPS Registry”. Autoimmun Rev. 2022;21(4):103055. doi: 10.1016/j.autrev.2022.103055Zhang B, Xing G. Thrombotic microangiopathy mediates poor prognosis among lupus nephritis via complement lectin and alternative pathway activation. Front Immunol. 2022;13:1081942. doi: 10.3389/fimmu.2022.1081942Zhang B, Xing G. Thrombotic microangiopathy mediates poor prognosis among lupus nephritis via complement lectin and alternative pathway activation. Front Immunol. 2022;13:1081942. doi: 10.3389/fimmu.2022.1081942Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: Prevalence, clinical associations, and long-term outcome. Arthritis Rheum. 2004;50(8):2569-2579. doi: 10.1002/art.20433Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: Prevalence, clinical associations, and long-term outcome. Arthritis Rheum. 2004;50(8):2569-2579. doi: 10.1002/art.20433Wu LH, Yu F, Tan Y, Qu Z, Chen MH, Wang SX, et al. Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int. 2013;83(4):715-723. doi: 10.1038/ki.2012.409Wu LH, Yu F, Tan Y, Qu Z, Chen MH, Wang SX, et al. Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int. 2013;83(4):715-723. doi: 10.1038/ki.2012.409Wigerblad G, Kaplan MJ. Neutrophil extracellular traps in systemic autoimmune and autoinflammatory diseases. Nat Rev Immunol. 2023 May;23(5):274-288. doi: 10.1038/s41577-022-00787-0Wigerblad G, Kaplan MJ. Neutrophil extracellular traps in systemic autoimmune and autoinflammatory diseases. Nat Rev Immunol. 2023 May;23(5):274-288. doi: 10.1038/s41577-022-00787-0Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Primers. 2020;6(1):7. doi: 10.1038/s41572-019-0141-9Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Primers. 2020;6(1):7. doi: 10.1038/s41572-019-0141-9Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on lupus nephritis: Core curriculum 2020. Am J Kidney Dis. 2020;76(2):265-281. doi: 10.1053/j.ajkd.2019.10.017Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on lupus nephritis: Core curriculum 2020. Am J Kidney Dis. 2020;76(2):265-281. doi: 10.1053/j.ajkd.2019.10.017Цанян МЭ, Александрова ЕН, Соловьев СК, Насонов ЕЛ. Антитела к C1q при системной красной волчанке – биологический маркер активности, предиктор развития нефрита и неблагоприятного жизненного прогноза. Научно-практическая ревматология. 2013;51(1):71–75.Tsanyan ME, Aleksandrova EN, Solovyev SK, Nasonov EL. Anti-C1q antibodies in systemic lupus erythematosus are a biological marker of the activity of nephritis, a predictor for its development and a poor life prognosis. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2013;51(1):71-75 (In Russ.)Насонов ЕЛ, Авдеева АС. Иммуновоспалительные ревматические заболевания, связанные с интерфероном типа I: новые данные. Научно-практическая ревматология. 2019;55(4):452-461. doi: 10.14412/1995-4484-2019-452-461Nasonov EL, Avdeeva AS. Immunoinflammatory rheumatic diseases associated with type I interferon: New evidence. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57(4):452-461 (In Russ.) doi: 10.14412/1995-4484-2019-452-461Obrișcă B, Sorohan B, Tuță L, Ismail G. Advances in lupus nephritis pathogenesis: From bench to bedside. Int J Mol Sci. 2021;22(7):3766. doi: 10.3390/ijms22073766Obrișcă B, Sorohan B, Tuță L, Ismail G. Advances in lupus nephritis pathogenesis: From bench to bedside. Int J Mol Sci. 2021;22(7):3766. doi: 10.3390/ijms22073766Насонов ЕЛ, Попкова ТВ, Лила АМ. Белимумаб в лечении системной красной волчанки: 20 лет фундаментальных исследований, 10 лет клинической практики. Научно-практическая ревматология. 2021;59(4):367-383. doi: 10.47360/1995-4484-2021-367-383Nasonov EL, Popkova TV, Lila AM. Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(4):367-383 (In Russ.) doi: 10.47360/1995-4484-2021-367-383Панафидина ТА, Сохова МА, Попкова ТВ Черкасова МВ, Новиков АА, Александрова ЕН, и др. Клиническое значение концентраций лигандов BAFF и APRIL при системной красной волчанке. Научно-практическая ревматология. 2016;54(2):145-154. doi: 10.14412/1995-4484-2016-145-15Panafidina TA, Sokhova MA, Popkova TV, Cherkasova MV, Novikov AA, Aleksandrova EN, et al. Clinical value of BAFF and APRIL concentrations in systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2016;54(2):145-154 (In Russ.) doi: 10.14412/1995-4484-2016-145-15Yu C, Li P, Dang X, Zhang X, Mao Y, Chen X. Lupus nephritis: New progress in diagnosis and treatment. J Autoimmun. 2022;132:102871. doi: 10.1016/j.jaut.2022.102871Yu C, Li P, Dang X, Zhang X, Mao Y, Chen X. Lupus nephritis: New progress in diagnosis and treatment. J Autoimmun. 2022;132:102871. doi: 10.1016/j.jaut.2022.102871Bhargava R, Li H, Tsokos GC. Pathogenesis of lupus nephritis: the contribution of immune and kidney resident cells. Curr Opin Rheumatol. 2023;35(2):107-116. doi: 10.1097/BOR.0000000000000887Bhargava R, Li H, Tsokos GC. Pathogenesis of lupus nephritis: the contribution of immune and kidney resident cells. Curr Opin Rheumatol. 2023;35(2):107-116. doi: 10.1097/BOR.0000000000000887Paquissi FC, Abensur H. The Th17/IL-17 axis and kidney diseases, with focus on lupus nephritis. Front Med (Lausanne). 2021;8:654912. doi: 10.3389/fmed.2021.654912Paquissi FC, Abensur H. The Th17/IL-17 axis and kidney diseases, with focus on lupus nephritis. Front Med (Lausanne). 2021;8:654912. doi: 10.3389/fmed.2021.654912Chang A, Clark MR, Ko K. Cellular aspects of the pathogenesis of lupus nephritis. Curr Opin Rheumatol. 2021;33(2):197-204. doi: 10.1097/BOR.0000000000000777Chang A, Clark MR, Ko K. Cellular aspects of the pathogenesis of lupus nephritis. Curr Opin Rheumatol. 2021;33(2):197-204. doi: 10.1097/BOR.0000000000000777Robson KJ, Kitching AR. Tertiary lymphoid tissue in kidneys: Understanding local immunity and inflammation. Kidney Int. 2020;98(2):280-283. doi: 10.1016/j.kint.2020.04.026Robson KJ, Kitching AR. Tertiary lymphoid tissue in kidneys: Understanding local immunity and inflammation. Kidney Int. 2020;98(2):280-283. doi: 10.1016/j.kint.2020.04.026Kinloch AJ, Chang A, Ko K, Henry Dunand CJ, Henderson S, Maienschein-Cline M, et al. Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritis. Arthritis Rheumatol. 2014;66(12):3359-3370. doi: 10.1002/art.38888Kinloch AJ, Chang A, Ko K, Henry Dunand CJ, Henderson S, Maienschein-Cline M, et al. Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritis. Arthritis Rheumatol. 2014;66(12):3359-3370. doi: 10.1002/art.38888Gomez Mendez LM, Cascino MD, Garg J, Katsumoto TR, Brakeman P, Dall’Era M, et al. Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol. 2018;13(10):1502-1509. doi: 10.2215/CJN.01070118Gomez Mendez LM, Cascino MD, Garg J, Katsumoto TR, Brakeman P, Dall’Era M, et al. Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol. 2018;13(10):1502-1509. doi: 10.2215/CJN.01070118Koga T, Ichinose K, Tsokos GC. T cells and IL-17 in lupus nephritis. Clin Immunol. 2017 Dec;185:95-99. doi: 10.1016/j.clim.2016.04.010Koga T, Ichinose K, Tsokos GC. T cells and IL-17 in lupus nephritis. Clin Immunol. 2017 Dec;185:95-99. doi: 10.1016/j.clim.2016.04.010Zhao Y, Wei W, Liu ML. Extracellular vesicles and lupus nephritis – New insights into pathophysiology and clinical implications. J Autoimmun. 2020 Dec;115:102540. doi: 10.1016/j.jaut.2020.102540Zhao Y, Wei W, Liu ML. Extracellular vesicles and lupus nephritis – New insights into pathophysiology and clinical implications. J Autoimmun. 2020 Dec;115:102540. doi: 10.1016/j.jaut.2020.102540Momtaz M, Fayed A, Wadie M, Gamal SM, Ghoniem SA, Sobhy N, et al. Retrospective analysis of nephritis response and renal outcome in a cohort of 928 Egyptian lupus nephritis patients: A university hospital experience. Lupus. 2017;26(14): 1564-1570. doi: 10.1177/0961203317716320Momtaz M, Fayed A, Wadie M, Gamal SM, Ghoniem SA, Sobhy N, et al. Retrospective analysis of nephritis response and renal outcome in a cohort of 928 Egyptian lupus nephritis patients: A university hospital experience. Lupus. 2017;26(14): 1564-1570. doi: 10.1177/0961203317716320Tang Y, Qin W, Peng W, Tao Y. Development and validation of a prediction score system in lupus nephritis. Medicine (Baltimore). 2017;96(37):8024. doi: 10.1097/MD.0000000000008024Tang Y, Qin W, Peng W, Tao Y. Development and validation of a prediction score system in lupus nephritis. Medicine (Baltimore). 2017;96(37):8024. doi: 10.1097/MD.0000000000008024Park DJ, Kang JH, Lee JW, Lee KE, Kim TJ, Park YW, et al. Risk factors to predict the development of chronic kidney disease in patients with lupus nephritis. Lupus. 2017;26(11):1139-1148. doi: 10.1177/0961203317694257Park DJ, Kang JH, Lee JW, Lee KE, Kim TJ, Park YW, et al. Risk factors to predict the development of chronic kidney disease in patients with lupus nephritis. Lupus. 2017;26(11):1139-1148. doi: 10.1177/0961203317694257Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al. 2019 update of the Joint European League Against Rheumatism and European Renal Association-EuropeanDialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713-723. doi: 10.1136/annrheumdis-2020-216924Chen S, Tang Z, Zhang Y, Liu Z, Zhang H, Hu W, et al. Significance of histological crescent formation in patients with diffuse proliferative lupus nephritis. Am J Nephrol. 2013;38(6):445-452. doi: 10.1159/000356184Chen S, Tang Z, Zhang Y, Liu Z, Zhang H, Hu W, et al. Significance of histological crescent formation in patients with diffuse proliferative lupus nephritis. Am J Nephrol. 2013;38(6):445-452. doi: 10.1159/000356184Kammoun K, Jarraya F, Bouhamed L, Kharrat M, Makni S, Hmida MB, et al. Poor prognostic factors of lupus nephritis. Saudi J Kidney Dis Transpl. 2011;22(4):727-732.Kammoun K, Jarraya F, Bouhamed L, Kharrat M, Makni S, Hmida MB, et al. Poor prognostic factors of lupus nephritis. Saudi J Kidney Dis Transpl. 2011;22(4):727-732.Rekvig OP. SLE classification criteria: Is «The causality principle» integrated and operative - and do the molecular and genetical network, on which criteria depend on, support the definition of SLE as «a one disease entity» – A theoretical discussion. Autoimmun Rev. 2023;22(12):103470. doi: 10.1016/j.autrev.2023.103470Rekvig OP. SLE classification criteria: Is «The causality principle» integrated and operative - and do the molecular and genetical network, on which criteria depend on, support the definition of SLE as «a one disease entity» – A theoretical discussion. Autoimmun Rev. 2023;22(12):103470. doi: 10.1016/j.autrev.2023.103470Broder A, Mowrey WB, Khan HN, Jovanovic B, Londono-Jimenez A, Izmirly P, et al. Tubulointerstitial damage predicts end stage renal disease in lupus nephritis with preserved to moderately impaired renal function: A retrospective cohort study. Semin Arthritis Rheum. 2018;47(4):545-551. doi: 10.1016/j.semarthrit.2017.07.007BroderA, MowreyWB, KhanHN, JovanovicB, Londono-JimenezA, Izmirly P, et al. Tubulointerstitial damage predicts end stage renal disease in lupus nephritis with preserved to moderately impaired renal function: A retrospective cohort study. Semin Arthritis Rheum. 2018;47(4):545-551. doi: 10.1016/j.semarthrit.2017.07.007Wilson PC, Kashgarian M, Moeckel G. Interstitial inflammation and interstitial fibrosis and tubular atrophy predict renal survival in lupus nephritis. Clin Kidney J. 2018;11:207-218. doi: 10.1093/ckj/sfx093Wilson PC, Kashgarian M, Moeckel G. Interstitial inflammation and interstitial fibrosis and tubular atrophy predict renal survival in lupus nephritis. Clin Kidney J. 2018;11:207-218. doi: 10.1093/ckj/sfx093Sciascia S, Cozzi M, Barinotti A, Radin M, Cecchi I, Fenoglio R, et al. Renal fibrosis in lupus nephritis. Int J Mol Sci. 2022;23(22):14317. doi: 10.3390/ijms232214317Sciascia S, Cozzi M, Barinotti A, Radin M, Cecchi I, Fenoglio R, et al. Renal fibrosis in lupus nephritis. Int J Mol Sci. 2022;23(22):14317. doi: 10.3390/ijms232214317Yung S, Chan TM. Molecular and immunological basis of tubulo-interstitial injury in lupus nephritis: A comprehensive review. Clin Rev Allergy Immunol. 2017 Apr;52(2):149-163. doi: 10.1007/s12016-016-8533-zYung S, Chan TM. Molecular and immunological basis of tubulo-interstitial injury in lupus nephritis: A comprehensive review. Clin Rev Allergy Immunol. 2017 Apr;52(2):149-163. doi: 10.1007/s12016-016-8533-zRijnink EC, Teng YKO, Wilhelmus S, Almekinders M, Wolterbeek R, Cransberg K, et al. Clinical and histopathologic characteristics associated with renal outcomes in lupus nephritis. Clin J Am Soc Nephrol. 2017;12(5):734-743. doi: 10.2215/CJN.10601016Rijnink EC, Teng YKO, Wilhelmus S, Almekinders M, Wolterbeek R, Cransberg K, et al. Clinical and histopathologic characteristics associated with renal outcomes in lupus nephritis. Clin J Am Soc Nephrol. 2017;12(5):734-743. doi: 10.2215/CJN.10601016Hernandez-Molina G, García-Trejo LP, Uribe N, Cabral AR. Thrombotic microangiopathy and poor renal outcome in lupus patients with or without an tiphospholipid syndrome. Clin Exp Rheumatol. 2015;33(4):503-508.Hernandez-Molina G, García-Trejo LP, Uribe N, Cabral AR. Thrombotic microangiopathy and poor renal outcome in lupus patients with or without an tiphospholipid syndrome. Clin Exp Rheumatol. 2015;33(4):503-508.Mejía-Vilet JM, Córdova-Sánchez BM, Uribe-Uribe NO, Correa-Rotter R, Morales-Buenrostro LE. Prognostic significance of renal vascular pathology in lupus nephritis. Lupus. 2017;26(10): 1042-1050. doi: 10.1177/0961203317692419Mejía-Vilet JM, Córdova-Sánchez BM, Uribe-Uribe NO, Correa-Rotter R, Morales-Buenrostro LE. Prognostic significance of renal vascular pathology in lupus nephritis. Lupus. 2017;26(10): 1042-1050. doi: 10.1177/0961203317692419Li C, Yap DYH, Chan G, Wen YB, Li H, Tang C, et al. Clinical outcomes and clinico-pathological correlations in lupus nephritis with kidney biopsy showing thrombotic microangiopathy. J Rheumatol. 2019;46(11):1478-1484. doi: 10.3899/jrheum.180773Li C, Yap DYH, Chan G, Wen YB, Li H, Tang C, et al. Clinical outcomes and clinico-pathological correlations in lupus nephritis with kidney biopsy showing thrombotic microangiopathy. J Rheumatol. 2019;46(11):1478-1484. doi: 10.3899/jrheum.180773Silvariño R, Sant F, Espinosa G, Pons-Estel G, Solé M, Cervera R, et al. Nephropathy associated with antiphospholipid antibodies in patients with systemic lupus erythematosus. Lupus. 2011;20(7):721-729. doi: 10.1177/0961203310397410Silvariño R, Sant F, Espinosa G, Pons-Estel G, Solé M, Cervera R, et al. Nephropathy associated with antiphospholipid antibodies in patients with systemic lupus erythematosus. Lupus. 2011;20(7):721-729. doi: 10.1177/0961203310397410

The authors declare that there are no conflicts of interest present.